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Introduction
Herein, we describe our experience with six Pompe
patients in South India from September 2007 to July
2012. All patients were diagnosed at our centre by clini-
cal exam and confirmed with enzyme assays and DNA
analyses.
Results
A total of six patients (4 months to 12 months, mean
7.33 months) were diagnosed during the study period.
Three presented to cardiologists for breathlessness and
infiltrative hypertrophic cardiomyopathy. All had motor
delay with severe hypotonia and head lag, respiratory
distress, and transaminitis. Three other children pre-
sented with hypotonia and motor delay, and one of
these was diagnosed during an episode of pneumonia.
Novel mutations were found in some of these children.
Four of six were born to consanguineous parents, and
two of six were able to receive ERT. Through the
INCAP programme on a compassionate basis, our
patient was the first to receive ERT for Pompe disease
in India. The first child started therapy at 8 months of
age, and the second at 15 months. Initial improvements
were noted in both; however, the first child stopped
treatment and died 2 months later at 14 months due to
respiratory failure. The second child received 10 infu-
sions and died from progressive respiratory failure at
2 years of age. The other three children died within 2
months of the diagnoses, and one died at 12 months. In
two families, we performed antenatal diagnoses using
enzyme estimation via amniocentesis and the next preg-
nancies were not affected.
Conclusion
Enzyme replacement therapy started at the later ages of
8 and 15 months, respectively, was not effective in
infantile onset Pompe disease. The non-availability of
governmental support has made ERT virtually out of
reach for Indian Pompe patients. Antenatal diagnosis is,
however, effective at reducing the disease burden in this
highly consanguineous population.
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